v3.25.3

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Research and development expenses	$ 9,730	$ 12,653	$ 32,320	$ 24,228
General and administrative expenses	4,604	4,249	13,804	12,031
Total operating expenses	14,334	16,902	46,124	36,259
Loss from operations	(14,334)	(16,902)	(46,124)	(36,259)
Other income :
Interest income and other, net	1,426	2,283	4,654	6,893
Total other income	1,426	2,283	4,654	6,893
Net loss	$ (12,908)	$ (14,619)	$ (41,470)	$ (29,366)
Net loss per share, basic (in dollars per share)	$ (0.4)	$ (0.45)	$ (1.28)	$ (0.95)
Net loss per share, diluted (in dollars per share)	$ (0.4)	$ (0.45)	$ (1.28)	$ (0.95)
Weighted-average shares outstanding, basic (in shares)	32,464,893	32,143,336	32,286,188	31,036,271
Weighted-average shares outstanding, diluted (in shares)	32,464,893	32,143,336	32,286,188	31,036,271
Other comprehensive income:
Net loss	$ (12,908)	$ (14,619)	$ (41,470)	$ (29,366)
Net unrealized gain (loss) on marketable securities	41	464	(113)	411
Total comprehensive loss	$ (12,867)	$ (14,155)	$ (41,583)	$ (28,955)

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5

Sagimet Biosciences Inc. 10-Q